Semaglutide works by mimicking the GLP-1 hormone that signals fullness, while tirzepatide activates both GLP-1 and GIP pathways, which may enhance metabolic effects and appetite control
This controversy encompasses several critical aspects, including regulatory approval and off-label use, the balance of efficacy versus potential risks, cost and accessibility, equity in resource allocation, and the broader implications of medicalizing obesity
The results showed that abdominal fat percentage decreased by 2.6, 2.8, and 6.1 percentage points in the exercise, Lira, and combination groups compared to placebo
To provide clearer guidance, here is an at-a-glance symptom table: Factors that increase the risk of diarrhoea Not everyone who takes semaglutide experiences diarrhoea
2 Week between each session